GLP-1 Drug Adds 12% to Lifespan in Late-Life Female Mice
Late-stage semaglutide given to aged female mice extended median lifespan by 12.4% while improving spatial memory and reducing cellular senescence. The drug operates as a calorie-restriction mimetic without the inconvenience of not eating.
- Treatment began at 20 months of age — roughly the human equivalent of late middle age
- Improvements spanned glucose regulation, motor endurance, and chronic inflammation markers
- Effect was female-specific; male mice showed no equivalent lifespan benefit